BIOVERATIV INC Zu einer Liste hinzufügen
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
William Sibold
PSD | President | - | 08.03.18 |
Joann Nestor
SEC | Corporate Secretary | - | - |
| Corporate Officer/Principal | - | - | |
Timothy Harris
PRN | Corporate Officer/Principal | 74 | 01.02.17 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
William Sibold
PSD | President | - | 08.03.18 |
Philippe Sauvage
BRD | Director/Board Member | - | 08.03.18 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 1 | 108 223 644 | 107 993 510 ( 99,79 %) | 0 | 99,79 % |
Unternehmenskontakt
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Bioverativ Therapeutics, Inc.
 Bioverativ Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bioverativ Therapeutics, Inc. develops pharmaceutical products. It develops medicines for chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders. The company is headquartered in Cambridge, MA. |
Pharmaceuticals: Major
|
Sektor
| % 1. Jan. | Kap. | |
|---|---|---|
| +3,42 % | 106 Mrd. | |
| +7,02 % | 23,47 Mrd. | |
| -14,87 % | 21,9 Mrd. | |
| -7,05 % | 18,77 Mrd. | |
| -38,55 % | 17,85 Mrd. | |
| -8,75 % | 16,78 Mrd. | |
| +6,40 % | 14,41 Mrd. | |
| +35,18 % | 12,86 Mrd. | |
| +316,09 % | 8,78 Mrd. |
